Share Fund
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
| Scheme Class | Equity |
| Scheme Category | Sector - Healthcare |
| Expense Ratio | 1.23% |
| Min subscription | ₹ 5,000 |
| Scheme Type | Open-ended |
| Scheme AUM (in Crs.) | ₹ 1,037 |
| AMC AUM (in Crs.) | ₹ 1,59,694 |
| Min Addition Subscription | ₹ 1,000 |
| Benchmark Type | BSE Healthcare PR |
| Exit Load | Exit load of 1.0%, if redeemed between (0-30) days. No Exit load, if redeemed after 30 days. |
| Fund | Min SIP Inv. | Min Inv. | Returns 3Y |
|---|---|---|---|
SBI Healthcare Opportunities Fund - Direct Plan | 0 | 0 | 30.25% |
SBI Healthcare Opportunities Fund - Direct Plan | 0 | 0 | 30.25% |
Nippon India Pharma Fund - Direct Plan | 1000 | 1000 | 26.24% |
UTI Healthcare Fund - Direct Plan | 0 | 0 | 27.9% |
Nippon India Pharma Fund - Direct Plan | 1000 | 1000 | 26.24% |
UTI Healthcare Fund - Direct Plan | 0 | 0 | 27.9% |
| Company | Holding Type | Asset(%) |
|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | 12 |
Cipla Ltd | Equity | 6 |
Dr Reddy's Laboratories Ltd | Equity | 5 |
Ajanta Pharma Ltd | Equity | 5 |
Procter & Gamble Health Ltd | Equity | 4 |
Apollo Hospitals Enterprise Ltd | Equity | 4 |
Glenmark Pharmaceuticals Ltd | Equity | 4 |
Divi's Laboratories Ltd | Equity | 3 |
Alkem Laboratories Ltd | Equity | 3 |
Fortis Healthcare Ltd | Equity | 3 |
| Asset | Percent |
|---|---|
Equity | 99 |
Cash | 1 |
Cash - Repurchase Agreement | 0 |
| Sector | Percent |
|---|---|
Healthcare | 98 |
Basic Materials | 1 |
Cash | 1 |
Cash - Repurchase Agreement | 0 |
Equity | 0 |
Fund Manager
Kamal Gada
3+ years of experience
About
pms_care@uti.co.in
Phone
1800 26 61230
Address
PMS Division, UTI - Tower, Gn Block, Bandra Kurla Complex, Mumbai- 400051, Mumbai - 400051
